Abstract
The vaccine candidate CVnCoV (CUREVAC) showed surprisingly low efficacy in a recent phase 3 trial compared with other messenger RNA (mRNA) vaccines. Here we show that the low efficacy follows from the dose used and the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and is predicted by the neutralizing antibody response induced by the vaccine.
All Keywords
【초록키워드】 SARS-CoV-2, Efficacy, coronavirus, Vaccines, variant, severe acute respiratory syndrome Coronavirus, mRNA, phase 3 trial, vaccine candidate, respiratory, Neutralizing antibody response, dose, Messenger RNA, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, CureVac, predicted, the vaccine, 【제목키워드】 protection, Level, Relating,
【초록키워드】 SARS-CoV-2, Efficacy, coronavirus, Vaccines, variant, severe acute respiratory syndrome Coronavirus, mRNA, phase 3 trial, vaccine candidate, respiratory, Neutralizing antibody response, dose, Messenger RNA, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, CureVac, predicted, the vaccine, 【제목키워드】 protection, Level, Relating,
{{{ 추상적인 }}}
백신 후보인 CVnCoV(CUREVAC)는 최근 3상 시험에서 다른 메신저 RNA(mRNA) 백신에 비해 놀라울 정도로 낮은 효능을 보였다. 여기에서 우리는 낮은 효능이 사용된 용량과 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 변이체의 존재에 따르고 백신에 의해 유도된 중화 항체 반응에 의해 예측된다는 것을 보여줍니다.